Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 412-418

  Sigsgaard, T ^b   Herrstedt, J ^c   Andersen, L J ^a   Havsteen, H ^c   Langer, S W ^c   Kjaerbol A G ^c   Lund, H ^c   Kjaer M ^a   Dombernowsky, P ^c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c NONE

Author keywords

Anti emetics; Dopamine D2 antagonist; Granisetron; Metopimazine; Multiple cycles; Prednisolone

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EPIRUBICIN; FLUOROURACIL; GRANISETRON; METHOTREXATE; METOPIMAZINE; PREDNISOLONE; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; GLUCOCORTICOIDS; GRANISETRON; HUMANS; ISONIPECOTIC ACIDS; METHOTREXATE; MIDDLE AGED; NAUSEA; PREDNISOLONE; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0032902064     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690372     Document Type: Article

References (48)

1. Aapro MS (1991) Controling emesis related to cancer therapy. Eur J Cancer 27: 356-361
2. Adams VR and Valley AW (1995) Granisetron: the second serotonin-receptor antagonist. Ann Pharmacother 29: 1240-1251
3. Andrews PLR and Davis CJ (1993) The mechanism of emesis induced by anticancer therapies. In Emesis in Anticancer Therapy, 1st Edn, Andrews PLA and Sanger GJ (eds), pp. 113-161. Chapman & Hall: London
4. Blijham HG (1992) Does granisetron remain effective over multiple cycles? Eur J Cancer 28A: S17-S21
5. Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Laurine E, Spielmann M, Tubiana-Hulin M, Paes D and Bons J (1990) A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8: 1063-1069
6. Campora E, Simoni C and Rosso R (1994) Tropisetron verso ondansetron nella preventione e controllo dellémesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operato. Minerva Med 85: 25-31
7. Cersosimo RJ and Karp DD (1986) Adrenal corticosteroids as antiemetics during cancer chemotherapy. Pharmacotherapy 6: 118-127
8. Chiara S, Campora E, Lionetto R, Bruzzi P and Rosso R (1987) Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10: 264-267
9. Clavel M, Soukop M and Greenstreet YLA (1993) Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 50: 180-183
10. Coleman RE, Twelves CJ, O'Reilly SM, Rubens RD, Richards MA and Harper PG (1991) Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting. Eur J Cancer 27: 1062-1063
11. de Wet M, Falkson G and Rapoport L (1993) Repeated use of granisetron in patients receiving cytostatic agents. Cancer 71: 4043-4049
12. De Wit R, Schmitz PIM, Verweij J, De Boer-Dennart M, De Mulder PHM, Planting AST, Van Der Burg MEL and Stoter G (1996) Analysis of cumultative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 14: 644-651
13. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71-85
14. Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, Latteri MA and Gebbia N (1994) Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 74: 1945-1952
15. Gez E, Strauss N, Vitzhaki N, Cass Y and Edelmann DZ (1992) Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. Cancer Chemother Pharmacol 30: 229-232
16. Havsteen H and Kjær M (1996) Antiemetic treatment with two different doses of methylprednisolone in breast cancer patients: a double-blind randomized crossover study with evaluation of efficacy parameters. Anti-Cancer Drugs 7: 535-542
17. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP and Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328: 1076-1080
18. Herrstedt J, Sigsgaard T, Angelo HR, Kampmann JP and Hansen M (1997) Dose-finding study of oral metopimazine. Support Care Cancer 5: 38-43
19. Ibrahim EM, Al-Idrissi HY, Ibrahim A, Absood G, Al-Dossary E, Al-Jammaa A, Al-Ethan S and Eliopoulos A (1986) Antiemetic efficacy of high-dose dexamethasone: Randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol 22: 283-288
20. Israel L and Rodary C (1978) Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy: results of two controlled studies. J Int Med Res 6: 235-240
21. Italian Group for Antiemetic Research (1994) Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol 5: 585-589
22. Italian Group for Antiemetic Research (1995a) Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 13: 2417-2426
23. Italian Group for Antiemetic Research (1995b) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl Med 332: 1-5
24. Jones A, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, Sikora K, Carney DN and Cunningham D (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483-487
25. Kaasa S, Kvaløy S, Dicato MA, Ries F, Huys JV, Royer E and Carruthers L (1990) A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study. Eur J Cancer 26: 311-314
26. Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M and Pater J (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 1050-1057
27. Koo WH and Ang PT (1996) Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7: 71-74
28. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C and Groshen S (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7: 108-114
29. Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, Wilson KS, Latreille J, Potvin M, Warner E, Pritchard KI, Palmer M, Zee B and Pater JL (1993) Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 328: 1081-1084
30. Markman M, Sheidler V, Ettinger DS, Quaskey SA and Mellits ED (1984) Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311: 549-552
31. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E and Upadhyaya B (1991) Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubucin and cyclophosphamide. Eur J Cancer 27: 1137-1140
32. Martin M, Diaz-Rubio E, Casado A, Dominguez S and Sastra J (1992) Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer 28: 430-432
33. Marty M (1990) A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard enti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26: S28-S32
34. Matsui K, Fukuoka M, Takada M, Kusunoki Y, Yana T, Tamura K, Yoshida T, Iida K, Hirashima T, Tsukada H, Ushijima S, Miyawaki H and Masuda N (1996) Randomized trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer 73: 217-221
35. Moertel CG and Reitemeier RJ (1973) Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 13: 283-287
36. Moreno I, Rosell R, Abad A, Barnadas A, Carles J, Ribelles N, Solano V and Font A (1992) Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 28A: 1344-1347
37. Münstedt K, Milch W, Blaunth-Eckmeyer E, Spänle A, Vahrson H and Reimer C (1995) Prevention of cisplatinum-induced delayed emesis and nausea. Onkologie 18: 23-26
38. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W and Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16: 754-760
39. Pollera CF, Nardi M, Marolla P, Pinnaro P, Terzoli E and Giannarelli D (1989) Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol 12: 524-529
40. Roila F, Basurto C, Minotti V, Ballatori E, Tonato M and Del Favero A (1988) Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. Oncology 45: 346-349
41. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Santi E, Penza O, Ballatori E and Del Favero A (1991) Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 14: 238-242
42. Silva RR, Bascioni R, Giorgi F, Acito L, De Signoribus G, Marcellini M, Menichetti ET and Giuliodori L (1996) Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Support Care Cancer 4: 287-290
43. Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, Kerr D, Khanna S, Smyth J, Coleman R, Cunningham D, Powels T, Davidson N, Hutcheon A, Green J, Slater A, Rustin G and Carney D (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49: 295-304
44. Stewart A, McQuade B, Cronje JDE, Goedhals L, Gudgeon A, Curette L, Froger X, Tubiana-Hulin M, Laplaige P, Roberts JT, Mcrae J, Forster J, Parasuraman TV and Butcher M (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicenter, double-blind, double-dummy, randomised parallel-group study. Oncology 52: 202-210
45. Tonato M, Roila F and Del Favero A (1991) Methodology of antiemetic trials: A review. Ann Oncol 2: 107-114
46. Vallejo C, Rabinovich M, Leone B and Gonzalez J (1988) Toxicity and dose-response of intravenous (i.v.) metopimazine (MPZ) as preventive of high-dose cisplatin (CDDP)-induced emesis. Proc Am Soc Clin Oncol 7: 286 (Abstract)
47. Warr D, Willan A, Fine S, Wilson K, Davis A, Erlichman C, Rusthoven J, Lofters W, Osoba D, Laberge F, Latreille J and Pater J (1991) Superiority of granisetron to dexamethasone plus pro0chlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83: 1169-1173
48. World Health Organisation (1979) Handbook for Reporting Results of Cancer Treatment. World Health Organisation: Bask